CA2776651C - Tricyclo-phosphorothioate dna - Google Patents
Tricyclo-phosphorothioate dna Download PDFInfo
- Publication number
- CA2776651C CA2776651C CA2776651A CA2776651A CA2776651C CA 2776651 C CA2776651 C CA 2776651C CA 2776651 A CA2776651 A CA 2776651A CA 2776651 A CA2776651 A CA 2776651A CA 2776651 C CA2776651 C CA 2776651C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid molecule
- dna
- tricyclo
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014535113A JP6181653B2 (ja) | 2011-10-13 | 2012-10-12 | トリシクロ−ホスホロチオエートｄｎａ |
| ES12770503.6T ES2651216T3 (es) | 2011-10-13 | 2012-10-12 | Triciclo-ADN fosforotioato |
| CA2851970A CA2851970A1 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate dna |
| US14/351,733 US9738891B2 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate DNA |
| AU2012322903A AU2012322903B2 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate dna |
| PCT/EP2012/070349 WO2013053928A1 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate dna |
| BR112014009066A BR112014009066B8 (pt) | 2011-10-13 | 2012-10-12 | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica |
| CN201280057688.6A CN104245935B (zh) | 2011-10-13 | 2012-10-12 | 三环硫代磷酸酯dna |
| EP12770503.6A EP2766479B1 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate dna |
| IL231983A IL231983B (en) | 2011-10-13 | 2014-04-07 | Dna containing tricyclo-phosphorothioate |
| IN3463DEN2014 IN2014DN03463A (https=) | 2011-10-13 | 2014-04-30 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546942P | 2011-10-13 | 2011-10-13 | |
| US61/546.942 | 2011-10-13 | ||
| EP11185129.1 | 2011-10-13 | ||
| EP11185129.1A EP2581448B1 (en) | 2011-10-13 | 2011-10-13 | Tricyclo-phosphorothioate DNA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2776651A1 CA2776651A1 (en) | 2013-04-13 |
| CA2776651C true CA2776651C (en) | 2021-06-08 |
Family
ID=44799824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2776651A Active CA2776651C (en) | 2011-10-13 | 2012-04-27 | Tricyclo-phosphorothioate dna |
| CA2851970A Abandoned CA2851970A1 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate dna |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2851970A Abandoned CA2851970A1 (en) | 2011-10-13 | 2012-10-12 | Tricyclo-phosphorothioate dna |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9738891B2 (https=) |
| EP (2) | EP2581448B1 (https=) |
| JP (1) | JP6181653B2 (https=) |
| CN (1) | CN104245935B (https=) |
| AU (1) | AU2012322903B2 (https=) |
| BR (1) | BR112014009066B8 (https=) |
| CA (2) | CA2776651C (https=) |
| DK (1) | DK2581448T3 (https=) |
| ES (2) | ES2535654T3 (https=) |
| IL (1) | IL231983B (https=) |
| IN (1) | IN2014DN03463A (https=) |
| PL (1) | PL2581448T3 (https=) |
| PT (1) | PT2581448E (https=) |
| WO (1) | WO2013053928A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| CN112574988A (zh) | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| LT2499249T (lt) | 2009-11-12 | 2018-12-27 | The University Of Western Australia | Priešprasmės molekulės ir patologijų gydymo būdai |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| NZ731587A (en) | 2013-03-14 | 2021-07-30 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| JP6618910B2 (ja) | 2013-09-05 | 2019-12-11 | サレプタ セラピューティクス，インコーポレイテッド | 酸性α−グルコシダーゼにおけるアンチセンス誘導エクソン２包含 |
| WO2015036451A1 (en) | 2013-09-11 | 2015-03-19 | Synthena Ag | Nucleic acids and methods for the treatment of pompe disease |
| WO2016016449A1 (en) | 2014-07-31 | 2016-02-04 | Association Institut De Myologie | Treatment of amyotrophic lateral sclerosis |
| BR112017004056A2 (pt) | 2014-09-12 | 2017-12-05 | Biogen Ma Inc | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| EP3353301A1 (en) | 2015-09-21 | 2018-08-01 | Association Institut de Myologie | Antisense oligonucleotides and uses thereof |
| EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| CA3021267A1 (en) | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| CN109477109B (zh) | 2016-04-29 | 2022-09-23 | 萨勒普塔医疗公司 | 靶向人lmna的寡核苷酸类似物 |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| TWI737736B (zh) | 2016-05-24 | 2021-09-01 | 美商薩羅塔治療公司 | 製備磷醯二胺嗎啉代寡聚物之方法 |
| MA45183A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| MA49775A (fr) | 2016-05-24 | 2020-06-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| TW201811807A (zh) | 2016-06-30 | 2018-04-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| WO2018055577A1 (en) * | 2016-09-23 | 2018-03-29 | Synthena Ag | Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof |
| US11118179B2 (en) | 2016-09-23 | 2021-09-14 | Synthena Ag | Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof |
| IL297528A (en) | 2016-12-19 | 2022-12-01 | Sarepta Therapeutics Inc | Exon-skipping oligomer conjugates for muscular dystrophy |
| SMT202200366T1 (it) | 2016-12-19 | 2022-11-18 | Sarepta Therapeutics Inc | Coniugati di oligomeri per salto di esone per distrofia muscolare |
| SI3554554T1 (sl) | 2016-12-19 | 2023-02-28 | Sarepta Therapeutics, Inc. | Oligomerni konjugati, ki preskakujejo ekson za mišično distrofijo |
| CN110536694A (zh) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| WO2018193428A1 (en) | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
| KR102778110B1 (ko) * | 2017-04-20 | 2025-03-10 | 신테나 아게 | 트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도 |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| WO2019067979A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| JP2020536058A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| WO2019067975A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| MX2021006737A (es) | 2018-12-13 | 2021-09-23 | Sarepta Therapeutics Inc | Conjugados de oligómeros de salto de exones para distrofia muscular. |
| EP3955966A1 (en) | 2019-04-18 | 2022-02-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| AU2020378619B2 (en) | 2019-11-06 | 2026-03-05 | Association Institut De Myologie | Combined therapy for muscular diseases |
| CR20220485A (es) | 2020-02-28 | 2022-11-10 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular smn2 |
| US20230139408A1 (en) | 2020-04-09 | 2023-05-04 | Association Institut De Myologie | Antisense sequences for treating amyotrophic lateral sclerosis |
| EP3978608A1 (en) | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51 |
| MX2024003690A (es) | 2021-09-30 | 2024-06-19 | Sarepta Therapeutics Inc | Oligonucleótidos antisentido que tienen una o más unidades abásicas. |
| JP2024539223A (ja) | 2021-10-22 | 2024-10-28 | サレプタ セラピューティクス， インコーポレイテッド | 末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| US20250066776A1 (en) | 2023-04-27 | 2025-02-27 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of chronic kidney disease |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| JP2003528024A (ja) | 1997-12-16 | 2003-09-24 | バレンティス・インコーポレーテッド | 製剤化された核酸分子の無針注入 |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| MXPA05011022A (es) | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| JP2010503707A (ja) * | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
| EP3443976A1 (en) * | 2007-06-29 | 2019-02-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN102231950A (zh) * | 2008-11-17 | 2011-11-02 | 安龙制药公司 | 用于核酸递送系统的可释放聚合脂质 |
| US20120149756A1 (en) * | 2009-04-10 | 2012-06-14 | Associatin Institut de Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
| WO2012115993A1 (en) | 2011-02-25 | 2012-08-30 | Lumitex, Inc. | Display front lighting device |
-
2011
- 2011-10-13 EP EP11185129.1A patent/EP2581448B1/en active Active
- 2011-10-13 PT PT111851291T patent/PT2581448E/pt unknown
- 2011-10-13 DK DK11185129T patent/DK2581448T3/en active
- 2011-10-13 PL PL11185129T patent/PL2581448T3/pl unknown
- 2011-10-13 ES ES11185129.1T patent/ES2535654T3/es active Active
-
2012
- 2012-04-27 CA CA2776651A patent/CA2776651C/en active Active
- 2012-10-12 BR BR112014009066A patent/BR112014009066B8/pt active IP Right Grant
- 2012-10-12 CN CN201280057688.6A patent/CN104245935B/zh active Active
- 2012-10-12 ES ES12770503.6T patent/ES2651216T3/es active Active
- 2012-10-12 WO PCT/EP2012/070349 patent/WO2013053928A1/en not_active Ceased
- 2012-10-12 AU AU2012322903A patent/AU2012322903B2/en active Active
- 2012-10-12 US US14/351,733 patent/US9738891B2/en active Active
- 2012-10-12 EP EP12770503.6A patent/EP2766479B1/en active Active
- 2012-10-12 JP JP2014535113A patent/JP6181653B2/ja active Active
- 2012-10-12 CA CA2851970A patent/CA2851970A1/en not_active Abandoned
-
2014
- 2014-04-07 IL IL231983A patent/IL231983B/en active IP Right Grant
- 2014-04-30 IN IN3463DEN2014 patent/IN2014DN03463A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015501144A (ja) | 2015-01-15 |
| CA2776651A1 (en) | 2013-04-13 |
| BR112014009066B1 (pt) | 2020-08-25 |
| WO2013053928A1 (en) | 2013-04-18 |
| EP2581448A1 (en) | 2013-04-17 |
| CA2851970A1 (en) | 2013-04-18 |
| IL231983A0 (en) | 2014-05-28 |
| ES2535654T3 (es) | 2015-05-13 |
| CN104245935A (zh) | 2014-12-24 |
| ES2651216T3 (es) | 2018-01-25 |
| HK1186205A1 (en) | 2014-03-07 |
| BR112014009066A2 (pt) | 2017-04-18 |
| AU2012322903B2 (en) | 2017-09-14 |
| CN104245935B (zh) | 2018-05-08 |
| JP6181653B2 (ja) | 2017-08-16 |
| EP2766479B1 (en) | 2017-09-13 |
| IN2014DN03463A (https=) | 2015-06-05 |
| PL2581448T3 (pl) | 2015-08-31 |
| BR112014009066A8 (pt) | 2018-01-09 |
| EP2766479A1 (en) | 2014-08-20 |
| AU2012322903A1 (en) | 2014-05-29 |
| IL231983B (en) | 2018-04-30 |
| EP2581448B1 (en) | 2015-01-28 |
| BR112014009066B8 (pt) | 2021-02-23 |
| DK2581448T3 (en) | 2015-04-27 |
| US20140296323A1 (en) | 2014-10-02 |
| US9738891B2 (en) | 2017-08-22 |
| PT2581448E (pt) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2776651C (en) | Tricyclo-phosphorothioate dna | |
| AU2018202634B2 (en) | Multimeric oligonucleotide compounds | |
| JP2023179431A (ja) | デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド | |
| EP2417257B1 (en) | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease | |
| US20120172415A1 (en) | Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy | |
| JP2019525918A (ja) | Ｓｍｎ２の調節のための化合物及び方法 | |
| EP3353301A1 (en) | Antisense oligonucleotides and uses thereof | |
| JP2019527549A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| EP4352229A1 (en) | Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use | |
| WO2019183005A1 (en) | 2'f-ana-let7 mediated utrophin upregulation for dmd therapy | |
| WO2024040041A1 (en) | Regulation of activity of rnai molecules | |
| HK1186205B (en) | Tricyclo-phosphorothioate dna | |
| Leumann et al. | des brevets (11) GG 0 000 000 L0 (12) LLLLLGGG GGGGGGGG LLLLL GGGGGGGG | |
| CN114829601A (zh) | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| CA2999192C (en) | Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof | |
| WO2024233864A2 (en) | Galnac-conjugated rnai oligonucleotides | |
| WO2024257848A1 (ja) | 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法 | |
| WO2023081822A1 (en) | Lipid conjugation for targeting oligodendrocytes of the central nervous system | |
| WO2023081823A1 (en) | Lipid conjugation for targeting astrocytes of the central nervous system | |
| HK40078456A (en) | Use of sbds inhibitors for treating hepatitis b virus infection | |
| EA049851B1 (ru) | РНКи-АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ PNPLA3, ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170222 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250516 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260331 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260331 |